Angle PLC Announces Parsortix HER2 Assay Showcased at AACR 2024
PARSORTIX HER2 ASSAY SHOWCASED AT PRESTIGIOUS INTERNATIONAL CANCER CONFERENCECTC HER2 assay being developed for HER2 targeted drugs and antibody drug...
Clinical Trial
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Toronto, Ontario--(Newsfile Corp. - April 7, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9) ("FSD Pharma" or...
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
SHANGHAI, China, April 07, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a...
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal...
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p<0.0001) through six months, with clinically...
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilitiesTORONTO, April 05, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc....
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic...
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2026NEW YORK, April 05,...
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
New development pathway significantly expands addressable patient population for IV Choline ChlorideIV Choline Chloride has the potential to become the...
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) (“Lipella,” “our”, “us” or the “Company”), a clinical-stage...
Medicure To Present Financial Results on April 9, 2024 Call at 8:30 AM ET for Quarter and Year Ended December 31, 2023
WINNIPEG, MB / ACCESSWIRE / April 4, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused...
Signifier Medical Technologies’ eXciteOSA Now Covered by Medicaid in South Carolina: Reaching a Wider Patient Population with Daytime Sleep Apnea Therapy
BOSTON--(BUSINESS WIRE)--Signifier Medical Technologies Limited (“Signifier”), a leader in medical technology for sleep-disordered breathing, is thrilled to announce that eXciteOSA...
MMJ BioPharma Cultivation Sues the DEA once again – Is the DEA a Rogue Agency?
The DEA Games Continue To Delay Legitimate Marijuana Clinical Trials and ResearchWASHINGTON, DC / ACCESSWIRE / April 4, 2024 /...
Otsuka Works with Verily to Launch Longitudinal Mental Health Registry to Advance Novel Research in Psychiatry
The ‘My Mental Health Journey’ registry is now enrolling U.S.-based adults experiencing symptoms of depression. The Otsuka-sponsored registry study is...
Halberd’s Patented Drug, LDN+, the Subject of a Limited Clinical Trial Under an Innovative Four-Company Cooperative Research and Development (CRADA) Contract
JACKSON CENTER, PA / ACCESSWIRE / April 4, 2024 / Halberd Corporation's (OTC PINK:HALB) Patented LDN+ Drug hits an enormous...
Participants in Nigeria Vaccinated in First-Ever Phase 2 Lassa Fever Vaccine Clinical Trial, Sponsored by IAVI
The CEPI-funded study will evaluate the safety, tolerability, and immunogenicity of IAVI's single dose Lassa fever vaccine candidateKey takeaways:Participants in...
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections
BOULDER, CO / ACCESSWIRE / April 4, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing...
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
Potentially differentiated, multivalent candidate encodes antigens matched to all four WHO-recommended flu strainsFor influenza A strains, geometric mean titers numerically...
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO): Fiscal Year 2024 Third Quarter Highlights Completed the sale of its PICC and Midline...
AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE
New Indication for Treatment of Pulmonary Embolism Enhances Device Utility in Critical Medical ScenariosLATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a...